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Members of the baculovirus p35 gene family encode proteins that specifically inhibit caspases, cysteine proteases that are involved in
apoptosis. To date, p35 homologs have only been found in baculoviruses. We have identified AMVp33, a gene from Amsacta moorei
entomopoxvirus with low but significant homology to baculovirus p35 genes. Expression of AMVp33 blocked apoptosis in several different insect
and human cell lines. Purified recombinant P33 protein was an efficient inhibitor of insect and human effector caspases, but not initiator caspases.
P33 was cleaved by effector caspases, and the resulting cleavage fragments stably associated with the caspases. Mutation of the predicted caspase
cleavage site in P33 eliminated cleavage, caspase inhibition and anti-apoptotic function. Thus, AMVp33 encodes a caspase inhibitor similar to
baculovirus P35 with a preference for effector caspases. This is the first report of a p35 homolog from any viral or cellular genome outside of the
baculovirus family.
© 2006 Elsevier Inc. All rights reserved.Keywords: Apoptosis; Caspase; Baculovirus; Entomopoxvirus; p35; InhibitorIntroduction
Apoptosis or programmed cell death is a normal physiolog-
ical process used to remove unwanted cells including damaged
and virus-infected cells. Upon receiving an apoptotic signal, a
group of cysteine proteases called caspases is activated. The
first caspases activated are the upstream initiator caspases which
then cleave and activate the downstream effector caspases
(Riedl and Shi, 2004). The effector caspases then selectively
cleave various cellular substrates leading to the eventual
dismantling of the cell (Hengartner, 2000). Caspases have a
high degree of substrate specificity and will only cleave proteins
that contain caspase recognition sites. Cleavage occurs
immediately after an Asp residue found in the recognition
site. In addition, the residues immediately surrounding the⁎ Corresponding author. Fax: +1 785 532 6653.
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doi:10.1016/j.virol.2006.08.043cleavage site Asp also play an important role in determining
whether a particular caspase will cleave a given protein (Riedl
and Shi, 2004).
Many viruses have evolved strategies to combat this process
and thereby allow for their multiplication. Baculoviruses
encode two families of anti-apoptotic genes, iap (inhibitor of
apoptosis) and p35, that can inhibit apoptosis induced by a wide
range of stimuli, including virus infection (Clem, 2005). One of
the most widely studied viral IAPs, Op-IAP from Orgyia
pseudotsugata M Nucleopolyhedrovirus is able to inhibit
apoptosis in insects and mammals by interacting with pro-
apoptotic proteins such as Hid, Reaper, Grim in Drosophila and
Smac/Diablo in mammals (Vucic et al., 1997, 1998; Wilkinson
et al., 2004; Wright and Clem, 2002). Unlike some cellular IAP
proteins, Op-IAP does not appear to function by directly
inhibiting caspases (Wright et al., 2005). P35, which was
originally found in the baculovirus Autographa californica M
Nucleopolyhedrovirus (AcMNPV), is also able to block
apoptosis in both insects and mammals. However, the mode
of action of P35 is quite different from that of baculoviral IAPs.
437J.C. Means et al. / Virology 358 (2007) 436–447P35 acts as a substrate inhibitor of effector caspases by virtue of
a solvent-exposed reactive site loop that contains a caspase
cleavage site, 84DQMD87. Upon cleavage after Asp87 by an
active caspase, a stable complex is formed between P35 and the
caspase (Bump et al., 1995; Fisher et al., 1999).
While IAP homologs are found in nearly all baculoviruses
examined to date, homologs of P35 exist in only a limited
number of other baculoviruses. The most divergent of these is
found in Spodoptera littoralis Nucleopolyhedrovirus (SlNPV)
and is called P49 (Du et al., 1999). P49 also acts as a substrate
inhibitor of caspases, but unlike P35 has been shown to inhibit
the activity of Drosophila initiator caspase DRONC (Jabbour et
al., 2002; Pei et al., 2002; Zoog et al., 2002).
Amsacta moorei entomopoxvirus (AmEPV) can infect the
gypsy moth Lymantria dispar and has been recently sequenced
and shown to contain a single functional iap gene (Li et al.,
2005). In addition to the iap gene, we identified a novel
homolog of the baculovirus p35 genes, which we have named
AMVp33. In this report, we show that P33 is a potent apoptosis
inhibitor, able to inhibit apoptosis in both insect and mammalian
cells, and functions to regulate apoptosis by acting as a substrate
inhibitor of effector caspases.Fig. 1. P33 alignment and predicted structure. (A) Alignment of the predicted amin
represent identical amino acids found in all 3 sequences, blue bars represent identical a
acids. The known caspase cleavage sites in P35 and P49 and the putative cleavage s
Predicted structures of AmEPV P33, SlNPV P49 and AcMNPV P35. Computer-assis
the 3D-PSSM Web server. Arrows indicate the positions of caspase cleavage sites.Results and discussion
P33 structure
As part of a search for potential anti-apoptotic genes, we
performed a standard BLAST search using the AcMNPV p35
gene sequence and identified AMV010, an ORF found in
AmEPV with low but significant homology to p35 (Fig. 1A).
AMV010 encodes a predicted protein of 32.7 kDa which lacks
identifiable sequence motifs. To be consistent with the
nomenclature of other known p35 homologs, we have renamed
this gene AMVp33. At the amino acid level, the identity of the
predicted P33 protein to AcMNPV P35 was 25%. To determine
if the predicted structure of P33 correlated to its possible
function, we performed computer-assisted modeling of P33
based on the known structure of the caspase inhibitor P35. This
comparison predicted a similar overall structure to that of both
P35 and P49 (Fig. 1B). While computer-based protein structure
predictions are of limited value, the most significant aspect of
the computer-generated model was the potential for P33 to
contain a reactive site loop similar to that found in P35 and P49,
with a potential caspase cleavage site 87YNFD90 in the sameo acid sequences of AmEPV P33, AcMNPV P35 and SlNPV P49. Yellow bars
mino acids found in 2 of the 3 sequences, and green bars represent similar amino
ite in P33 are boxed. Sequence alignment was performed using Vector Nti. (B)
ted modeling of P33 and P49 was performed based on the structure of P35 using
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P35. Since P35 is a potent caspase inhibitor, we decided to
analyze the ability of P33 to inhibit apoptosis, and in particular
caspases.
P33 inhibits apoptosis induced by diverse stimuli
To test the ability of P33 to block caspase-dependent
apoptosis, we transiently expressed N-terminally HA-tagged
P33 in LD652Y, S2 and SF-21 cells and induced the cells to
undergo apoptosis with UV radiation. Immunoblot analysis was
performed to confirm expression of P33 in each cell type (Fig.
2A). P33 expression inhibited UV-induced apoptosis in all three
cell lines, to a degree comparable to that of P35 (Figs. 2B–C).Fig. 2. P33 blocks apoptosis induced by UV irradiation in insect cell lines. (A) Anti-H
transfection with plasmids expressing HA-tagged P33 or point mutant P33(D90A). La
and LD652Y cells were mock-transfected or transfected with plasmids expressing P33
cell viability was determined 24 h later. Each data point represents the mean of three
24 h after UV treatment. Magnification, ×400.P33 also blocked apoptosis induced by vHSGFP/P35del, a
mutant of AcMNPV that lacks p35 (Figs. 3A–B). P33
prevented apoptosis and allowed for virus replication as
indicated by the formation of polyhedra (Fig. 3A).
To assess the importance of the P33 predicted cleavage site
(YNFD90) for its anti-apoptotic function, Asp90 was substituted
with Ala. Although expressed at similar levels as wild-type P33
(Fig. 2A), the point mutant P33(D90A) failed to block apoptosis
induced by either UV irradiation or viral infection (Figs. 2B,
3B). In examining the sequence of P33, two other Asp residues
(Asp83 and Asp101) were found in the predicted reactive site
loop near Asp90. These Asp residues were mutated to Ala, and
the resulting point mutants were tested for their ability to block
apoptosis. P33(D83A) and P33(D101A) were able to preventA immunoblot of lysates from LD652Y, S2 and SF-21 cells collected 24 h after
nes labeled “Mock” represent lysates from mock-transfected cells. (B) SF-21, S2
, P33(D90A) or P35, and 24 h after transfection, the cells were UV-irradiated and
experiments±SE. (C) Photomicrographs of LD652Y, S2 and SF-21 cells taken
Fig. 3. P33 blocks AcMNPV-induced apoptosis. (A) SF-21 cells were mock-transfected or transfected with plasmids expressing P33, P35 or negative control
chloramphenicol acetyl transferase (CAT) and 24 h later the cells were infected with wild-type AcMNPVor vHSGFP/P35del at an MOI of 10 PFU/cell. At 96 h post
infection, the cells were photographed. Magnifications, ×400 (i, iii, iv) or ×1000 (ii, v, vi). (B) SF-21, S2 and LD652Y cells were mock-transfected or transfected with
plasmids expressing P35, P33 or P33(D90A) and 24 h later infectedwith vHSGFP/P35del at anMOI of 10 PFU/cell. Cell viability was determined 24 h after infection. One
well of each was infected with AcMNPVexpressing P35 (vHSGFP), and cell viability was determined as above. The data represent the mean of three experiments±SE.
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efficiently as wild-type P33 (data not shown), further
illustrating the importance of residue Asp90.
P33 expression suppresses caspase activity in cells
To determine whether inhibition of apoptosis by P33
correlated with reduced caspase activity, whole cell lysates
from either mock-transfected, P35- or P33-expressing cells
were harvested 12 h after UV or viral infection and caspase
activity was determined using the fluorogenic caspase sub-
strates Ac-IETD-AFC (to measure initiator caspase activity) or
Ac-DEVD-AFC (to measure effector caspase activity). P33-
expressing cells showed significantly reduced effector caspase
activity as compared to mock-transfected cells, comparable to
that seen with P35 (Fig. 4). However, initiator caspase (IETD)
activity was unaffected by P33 expression, again similar to what
was seen in P35-expressing cells. These results suggest that
P33, like P35, functions by inhibiting effector caspase activity.
The point mutant P33(D90A) was unable to inhibit either typeof caspase activity, which correlated with its inability to block
apoptosis (Fig. 4).
P33 is a direct inhibitor of caspases
Next, we determined if P33 was a direct inhibitor of caspases
by purifying recombinant C-terminally His6-tagged P33 from
bacteria and testing its ability to inhibit purified recombinant
caspases. We used the fluorogenic caspase substrates Ac-
DEVD-AFC (DrICE, DCP-1, Sf-caspase-1, caspase-3), Ac-
IETD-AFC (DRONC) or Ac-LEHD-AFC (caspase-9) to
perform a dose–response assay, with increasing amounts of
P33-His6. The results showed that the effector caspases Sf-
caspase-1 from Spodoptera frugiperda, human caspase-3 and
DrICE and DCP-1 from Drosophila were efficiently inhibited
by purified P33-His6 (Figs. 5A–C, E), but the initiator caspases
DRONC from Drosophila and human caspase-9 were not
efficiently inhibited by P33-His6, with approximately 4-fold
excess showing no inhibition. A 200-fold excess of P33-His
was able to inhibit DRONC and caspase-9 (Figs. 5D and F),
Fig. 4. P33 expression prevents effector but not initiator caspase activity in cells. (A) SF-21, S2 or LD652Y cells were either left untreated, infected with control virus
vHSGFP or mock-transfected or transfected with plasmids encoding P35, P33 or P33(D90A) and 24 h later infected with p35 deletion virus vHSGFP/P35del. Twelve
hours later, caspase activity was determined using Ac-DEVD-AFC or Ac-IETD-AFC as substrate. The lysates used for the DEVD assay were diluted 50-fold before
use in the assay to maintain enzyme activity in the linear range. Panel (B) is similar to (A) except the cells were UV-irradiated 24 h after transfection instead of being
infected with vHSGFP/P35del. Untreated cells were not irradiated or infected. Each data point represents the mean of three experiments±SE.
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caspases. However, given its lack of inhibition at lower
concentrations, P33 is probably not able to inhibit initiator
caspases under physiological conditions.
To assess the ability of the P33(D90A) mutant to inhibit
caspase activity in vitro, recombinant P33(D90A)-His6 was
incubated in increasing amounts with effector caspases. P33
(D90A)-His6 was unable to block the caspase activity of DrICE,
DCP-1, caspase-3 or Sf-caspase-1 (Fig. 6), indicating that
residue Asp90 is important for caspase inhibition.
Mechanism of caspase inhibition by P33
AcMNPV P35 is a substrate inhibitor of caspases. The P35
protein is cleaved at position Asp87 by caspases, and then the
P35 cleavage products become covalently linked to the caspase
by a thioester bond (Xu et al., 2001). To determine whether P33
acts by a similar mechanism, in vitro translated, 35S-labeled P33
was incubated with lysate prepared from LD652Y cells that had
been UV-irradiated or infected with vHSGFP/P35del. P33 was
cleaved by the apoptotic lysates, and this cleavage was inhibited
by the pan-caspase inhibitor z-VAD-fmk, indicating thatcaspases were involved in the cleavage (Fig. 7B). To further
determine if P33 was a substrate for caspases, recombinant
purified DrICE, DCP-1, Sf-caspase-1, caspase-3, caspase-9 or
DRONC was incubated with in vitro translated P33. P33 was
cleaved by the effector caspases caspase-3, DrICE, DCP-1 and
Sf-caspase-1 (Fig. 7C). Cleavage was not observed with
DRONC or caspase-9 (Fig. 7C). To determine whether the
cleavage fragments associated with the target caspase, we
immunoprecipitated the His-tagged caspases using anti-His
antibody. 35S-labeled P33 cleavage fragments associated with
the effector caspases caspase-3, DrICE, DCP-1, Sf-caspase-1,
but not with DRONC or caspase-9 (Fig. 7D). The point mutant
P33(D90A) was not cleaved by any of the caspases tested (Fig.
7C) and did not associate with any of the caspases (Fig. 7D),
indicating that Asp90 is likely the site of caspase cleavage in
P33.
Comparison of caspase inhibition by P33 and P35
To compare the caspase inhibiting ability of P33 in relation
to P35, increasing concentrations of recombinant P33 or P35
were incubated with recombinant effector caspases DrICE,
Fig. 5. P33 directly inhibits effector caspase activity in vitro. Recombinant purified (A) DrICE, (B) Sf-caspase-1, (C) DCP-1, (D) DRONC, (E) caspase-3 or (F) caspase-9 were incubated with increasing concentrations of
recombinant P33-His6, and caspase activity was determined using 0.2 μM of the indicated substrates. Caspase inhibitor z-VAD-fmk (100 μM) was used as a control.
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Fig. 6. P33(D90A) does not inhibit caspase activity in vitro. P33(D90A) (100 μM) was tested for its ability to inhibit recombinant effector caspases (A) DrICE, (B)
DCP-1, (C) caspase-3 or (D) Sf-caspase-1 (0.5 μM each) using the substrate Ac-DEVD-AFC. P33 and P35 were added at a concentration of 2 μM. The data represent
the mean of three experiments±SE.
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or caspase-9 and caspase activity was determined. Both P33 and
P35 inhibited effector caspase activity to a similar extent (Figs.
8A–B, D–E), but were unable to inhibit the initiator caspase
DRONC, except at 200-fold excess (Fig. 8C). It has been shown
previously that P35 inhibits caspase-9 in vitro, but not in vivo
(Ryan et al., 2002). While our results verified inhibition of
caspase-9 by P35, we did not observe inhibition of caspase-9 by
P33 unless P33 was in high molar excess (Fig. 8F). In addition,
P35 was cleaved by caspase-9 in vitro, but P33 was not (data
not shown). These results suggest that P33 is more similar to
P35 than to P49 since P49 is able to inhibit DRONC in addition
to effector caspases but that P33 differs from P35 in being
unable to inhibit human caspase-9 in vitro.
P33 protects mammalian cells against UV-induced apoptosis
Expression of AcMNPV P35 inhibits apoptosis in a wide
variety of organisms, ranging from nematodes to human cells.
To determine whether P33 could also protect against apoptosis
in a phylogenetically diverse organism, P33 was expressed in
the HT-1080 human fibroblastoma cell line and the cells were
UV-irradiated to induce apoptosis. P33-expressing cells were
protected against apoptosis compared to cells that were mock-
transfected (Figs. 9Ai, C), and this protection correlated with
reduced caspase activity (Fig. 9Aii). P33 was also able to blockapoptosis in human embryonic kidney 293 cells induced by UV
irradiation (Fig. 9B).
Conclusions
In this study, we have identified and characterized AMVp33,
the first homolog of p35 genes found outside of the
baculoviruses. Computer-assisted modeling of P33 showed an
overall predicted structure similar to that of P35, including a
potential reactive site loop and caspase cleavage site. Expression
of P33 was found to inhibit apoptosis induced by UV radiation
and baculovirus infection in cells from diverse organisms,
including insects and human. P33 was able to potently inhibit
effector caspases from phylogenetically diverse organisms, but
had only limited ability to inhibit initiator caspases. Thus, P33
appears to be more similar in action to P35 than to P49. Mutation
of the potential cleavage site, Asp90 resulted in complete loss of
anti-apoptotic activity and caspase inhibition and also eliminated
caspase cleavage of P33, indicating that Asp90 is likely a site for
caspase cleavage similar to that seen in P35 and P49. These
results indicate that P33 functions like P35 by acting as a
substrate inhibitor of effector caspases.
P35 family members are able to block apoptosis in diverse
organisms (Hay et al., 1994; Rabizadeh et al., 1993; Sugimoto
et al., 1994) and are among the most widely acting anti-
apoptotic proteins known. Despite this, P35 homologs have
Fig. 7. P33 is cleaved and associates stably with effector caspases. (A) Diagram of P33 showing the putative cleavage site D90 and the predicted 22 kDa (*′) and
11 kDa (*) cleavage fragments. (B) 35S-labeled P33 was incubated with lysates from untreated LD652Y cells, cells infected with vHSGFP/P35del or cells treated with
UV. The reactions were then analyzed by SDS-PAGE and autoradiography. The caspase inhibitor z-VAD-fmk was used to show that cleavage was due to caspase
activity. Migration of the cleavage fragments and full-length P33 (FL) is indicated. (C) Purified recombinant His6-tagged caspase-3, caspase-9, DRONC, DCP-1,
Sf-caspase-1 or DrICE (0.5 μM each) was incubated with 35S-labeled P33 or 35S-labeled P33(D90A) followed by SDS-PAGE and autoradiography. (D) 35S-labeled
P33 or 35S-labeled P33(D90A) was incubated with recombinant His6-tagged caspases (0.5 μM). The reactions were then immunoprecipitated with anti-His antibody,
and immunoprecipitated proteins were analyzed by SDS-PAGE and autoradiography.
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viruses, both of which infect only insects. Whether or not P35
homologs exist in cellular genomes or in the genomes of viruses
that infect higher organisms is still an unanswered question. The
reason for this may be that such homologs have evolutionarily
diverged to the point where the sequence identity is too low to
be recognized by currently available algorithms. However, it is
interesting to note that iap genes, which are also found in insect
viruses including baculoviruses, entomopoxviruses and irido-
viruses, do have readily recognizable homologs in higher
organisms, but have not been found in viruses that infect higher
organisms (with the exception of African swine fever virus,
which has an obligate stage in ticks). This work significantly
expands the P35 family of protease inhibitors and may aid in the
eventual identification of cellular P35 homologs.Materials and methods
Cells and viruses
S. frugiperda (SF-21), L. dispar (LD652Y) and Trichoplusia
ni (TN-368) cells were maintained in TC-100 medium
(Invitrogen) supplemented with 10% tryptose broth and 10%
fetal bovine serum (FBS) (Invitrogen).Drosophila S2 cells were
maintained in Schneider's medium (Invitrogen) supplemented
with 10% FBS. Human fibrosarcoma HT-1080 cells and human
embryonic kidney 293 cells were maintained in Dulbecco's
Modification of Eagle's Medium (DMEM) with 10% FBS.
Wild-type AcMNPV (L1 strain), vHSGFP, and the p35 deletion
virus vHSGFP/P35del (Clarke and Clem, 2002) were propa-
gated and titered by plaque assay using TN-368 cells.
Fig. 8. Comparison of P33 and P35 caspase inhibiting activity. Increasing concentrations of recombinant purified P33-His6 or P35-His6 were incubated with the
indicated caspases (0.5 μM), and caspase activity was determined using the indicated substrates. Each data point represents the mean of three experiments±SE.
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The P33(D90A) mutant was generated using the Quik-
Change Site-Directed Mutagenesis kit (Stratagene) with the
following primers: forward primer 5′-aatgtatataattttgccacaaa-
tattatatgt-3′ and reverse primer 5′-acatataatatttgtggcaaaattatata-
catt-3′, which resulted in mutation of the Asp residue at position
90 to Ala. The plasmid inserts were sequenced to verify the
mutation and to ensure the absence of inadvertent mutations.
Plasmid construction
For expression in insect cells, the AMVp33 gene was PCR
amplified from AmEPV genomic DNA (provided by Teri
Shors, University of Wisconsin-Oshkosh) using primers
containing ApaI and EcoRI sites to allow for cloning into
pHSEpiOpIAPVI+ (Vucic et al., 1997). The following primers
were used: forward primer 5′-gggcccgaatgtgttttaatgattatga-3′
and reverse primer 5′-gaattcttattcgactgtaatttttatattg-3′. The PCR
product was gel-purified with the Gel Extraction Kit (Qiaex II),
cloned into the pCRII vector (Invitrogen), digested with ApaI
and EcoRI and cloned into the pHSEpiOpIAPVI+ vector after
the coding sequence of Op-IAP was removed by digesting with
ApaI and EcoRI. This allowed for P33 to be expressed with the
HA tag in frame at the N-terminus. For expression in
mammalian cells, AMVp33 was cloned into the pcDNA3.1/
V5His TOPO TA vector (Invitrogen) using primers containing
BamHI and SacII sites. For recombinant protein production,AMVp33 or AcMNPV p35 genes were PCR amplified using
primers containing XhoI and NdeI sites to allow for cloning
into the pET23b expression vector (Novagen), which resulted
in expression in frame with C-terminal His6 tags. Point
mutations were constructed using the QuikChange kit (Strata-
gene). The nucleotide sequences of all constructs were verified
before use.
Recombinant protein expression and purification
His-tagged P33, P35, DRONC, DrICE, DCP-1 and Sf-
caspase-1 were expressed in BL21pLysS(DE)3 Escherichia
coli (Stratagene). Cultures were grown at room temperature to
OD600=0.4, at which time they were induced with 0.1 M IPTG
for 1 h. The bacteria were sonicated in Lysis Buffer A
(200 mM Tris–Cl pH 8.0, 0.4 M ammonium sulfate, 10 mM
MgCl2, 10% glycerol and protease inhibitor cocktail (Roche))
and purified using Talon Metal Affinity Resin (Clontech)
according to the manufacturer's instructions. Active human
recombinant caspase-3 and -9 were purchased from Chemicon
International.
Caspase assays
Purified recombinant caspase (caspase-3-His6, caspase-9-
His6, DRONC-His6, DrICE-His6, DCP-1-His6 or Sf-Caspase-
1-His6) (0.5 μM) was incubated with increasing concentrations
of P35-His6 or P33-His6 (0–100 μM) in caspase activity buffer
Fig. 9. P33 blocks UV-induced apoptosis in HT-1080 and HEK293 cells. (A) HT-1080 or (B) 293 cells were mock-transfected or transfected with plasmids expressing
P33 and 24 h after transfection the cells were UV-irradiated. Twenty four hours later viability (i) or 12 h later caspase activity (ii) was determined using Ac-DEVD-AFC
as substrate. The lysates were diluted 50-fold before use in the caspase assay to maintain enzyme activity in the linear range. Each data point represents the mean of
three experiments±SE. (C) Photomicrographs of HT-1080 cells that were mock-transfected (i, iii) or transfected with a plasmid expressing P33 (ii, iv) and either left
untreated (i, ii) or UV-irradiated (iii, iv). Pictures were taken 24 h after UV treatment. Magnification ×400.
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CHAPS, 10% sucrose, 5 mM DTT) for 4 h at 30 °C. All
caspase inhibitors and substrates were purchased from Enzyme
Systems Products. Following incubation, caspase substrate was
added to the reactions at a concentration of 0.2 μM (Ac-IETD-
AFC was used for DRONC, Ac-LEHD-AFC was used for
caspase-9 and Ac-DEVD-AFC was used for caspase-3, DrICE,
Sf-caspase-1 and DCP-1). In control reactions, the caspase
inhibitor zVAD-fmk was used at a concentration of 100 μM.
Caspase activity was determined as an increase in fluorescence
detection caused by the enzymatic cleavage of the substrate and
the release of AFC (7-amino-(trifluoromethyl)coumarin). The
reactions were analyzed fluorometrically (excitation 405 nm,
emission 535 nm), and activity was expressed in relative
arbitrary fluorescence units. When necessary, reactions were
diluted to maintain enzyme activity in the linear range as
indicated.
To determine caspase activity in SF-21, S2 and LD652Y
cells, plasmids encoding HA-tagged P33 or P35 were
transfected into the cells using a lipid reagent (Means et al.,2003) in TC-100 medium without FBS, and 4 (SF-21, LD652Y)
or 5.5 (S2) h later, the lipid–DNA mix was replaced with TC-
100 medium containing 10% FBS. Twenty-four hours after
transfection, the cells were UV-irradiated by placing on a
transilluminator for 10 min. Twelve hours after UV treatment,
cells were harvested in caspase activity buffer A and caspase
activity determined using Ac-DEVD-AFC or Ac-IETD-AFC as
substrate. For the p35 deletion virus, plasmids expressing P33
or P35 were transfected into SF-21, S2 and LD652Y cells as
described and 24 h after transfection cells were infected with
p35 deletion virus at an MOI of 10 PFU/cell. Twelve hours after
virus infection, cells were harvested and caspase activity
determined as described.
P33 structural modeling
Computer-assisted modeling of P33 was based on the
structure of AcMNPV P35 using the 3D-PSSM Web server
Biomolecular Modeling Laboratory at the Imperial Center
Research Fund.
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To examine expression of P33 constructs, LD652Y, S2 or
SF-21 cells were transfected as described above and samples
were harvested 24 h after transfection and analyzed by
immunoblotting using anti-HA.11 mouse monoclonal antibody
(Covance Research Products) at a concentration of 1:500, goat
anti-mouse IgG horseradish peroxidase-conjugated antibody
(1:20,000) and Supersignal chemiluminescent reagent (Pierce).
Viability assays
For UV viability, SF-21, LD652Y or S2 cells were
transfected with plasmids expressing enhanced green fluores-
cent protein (eGFP) (3 μg) and either P33, P33(D90A) or P35
(3 μg) and 24 h after transfection cells were UV-irradiated as
described above. Twenty-four hours after UV treatment, the
number of viable eGFP-positive cells remaining was deter-
mined by counting three fields of view under 400× magnifi-
cation and the percent viability was calculated relative to the
number of eGFP-positive cells at 1 h after UV treatment.
Cellfectin reagent (Invitrogen) was used for S2 cells, and a
liposome reagent (Means et al., 2003) was used for SF-21 and
LD652Y cells. For viability with the p35 deletion virus,
plasmids were introduced into cells as described above.
Twenty-four hours after transfection, cells were infected with
vHSGFP/P35del at an MOI of 10 PFU/cell and 24 h after
infection viability was determined as above. For viability in
HT-1080 and 293 cells, P33-expressing plasmid was co-
transfected with a plasmid expressing eGFP into cells using
Lipofectamine 2000 (Invitrogen). Twenty-four hours after
transfection, cells were UV-irradiated by placing on a
transilluminator for 10 min and viability was determined
24 h later as described above.
Marker rescue assay
Plasmids expressing P33, P35 or CAT were introduced into
SF-21 cells and infected with vHSGFP/P35del as described
above. Four days after infection, polyhedra formation was
examined by microscopy.
Caspase cleavage assay and co-immunoprecipitation
35S-P33 and 35S-P33(D90A) were synthesized using the
TNT T7/SP6 Coupled Reticulocyte Lysate System (Promega)
from the pCRII/P33 plasmid. Twenty microliters reticulocyte
lysate was then incubated with 1 μM caspase-3, caspase-9,
DRONC, DCP-1, Sf-caspase-1 or DrICE in caspase buffer A for
4 h at 37 °C. After incubation, SDS-PAGE was performed
followed by autoradiography. To determine if P33 cleavage
fragments associated with caspase, the caspase cleavage assay
was performed as described, and the reactions were then added
to 50 μl of protein G beads (Sigma) that had been preincubated
with anti-HIS antibody (His-Probe H-3, Santa Cruz Biotech-
nology) diluted 1:100 and rocked overnight at 4 °C. The beads
were washed 3 times with caspase buffer A, and bound proteinwas removed from the protein G beads by heating the samples at
100 °C in SDS-PAGE sample buffer for 5 min. SDS-PAGE and
autoradiography were then performed. To examine cleavage of
P33 using cell lysate, LD652Y cells were harvested 12 h after
UV or p35 deletion virus infection and incubated with 20 μl
reticulocyte lysate followed by SDS-PAGE and autoradiogra-
phy. As a control, caspase inhibitor zVAD-fmk (100 μM) was
added 4 h prior to treatment.
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